482 related articles for article (PubMed ID: 28801108)
21. Dual functional nanoparticles efficiently across the blood-brain barrier to combat glioblastoma
Jin Z; Piao L; Sun G; Lv C; Jing Y; Jin R
J Drug Target; 2021 Mar; 29(3):323-335. PubMed ID: 33108906
[TBL] [Abstract][Full Text] [Related]
22. Modeling of ultra-small lipid nanoparticle surface charge for targeting glioblastoma.
Mendes M; Miranda A; Cova T; Gonçalves L; Almeida AJ; Sousa JJ; do Vale MLC; Marques EF; Pais A; Vitorino C
Eur J Pharm Sci; 2018 May; 117():255-269. PubMed ID: 29486328
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in targeted drug delivery for the treatment of glioblastoma.
Mao M; Wu Y; He Q
Nanoscale; 2024 May; 16(18):8689-8707. PubMed ID: 38606460
[TBL] [Abstract][Full Text] [Related]
24. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
Agarwal S; Muniyandi P; Maekawa T; Kumar DS
Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
[TBL] [Abstract][Full Text] [Related]
25. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
Ganipineni LP; Danhier F; Préat V
J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
[TBL] [Abstract][Full Text] [Related]
26. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting.
Martins C; Araújo M; Malfanti A; Pacheco C; Smith SJ; Ucakar B; Rahman R; Aylott JW; Préat V; Sarmento B
Small; 2023 Jun; 19(22):e2300029. PubMed ID: 36852650
[TBL] [Abstract][Full Text] [Related]
27. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.
Jena L; McErlean E; McCarthy H
Drug Deliv Transl Res; 2020 Apr; 10(2):304-318. PubMed ID: 31728942
[TBL] [Abstract][Full Text] [Related]
28. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery.
Zhao J; Zhang B; Shen S; Chen J; Zhang Q; Jiang X; Pang Z
J Colloid Interface Sci; 2015 Jul; 450():396-403. PubMed ID: 25863222
[TBL] [Abstract][Full Text] [Related]
29. Glioblastoma Multiforme and Lipid Nanocapsules: A Review.
Aparicio-Blanco J; Torres-Suárez AI
J Biomed Nanotechnol; 2015 Aug; 11(8):1283-311. PubMed ID: 26295134
[TBL] [Abstract][Full Text] [Related]
30. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
31. Nose-to-brain drug delivery for the treatment of glioblastoma multiforme: nanotechnological interventions.
Kumar N; Khurana B; Arora D
Pharm Dev Technol; 2023 Dec; 28(10):1032-1047. PubMed ID: 37975846
[TBL] [Abstract][Full Text] [Related]
32. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
33. Recent Advances on Surface-Modified GBM Targeted Nanoparticles: Targeting Strategies and Surface Characterization.
Rodà F; Caraffi R; Picciolini S; Tosi G; Vandelli MA; Ruozi B; Bedoni M; Ottonelli I; Duskey JT
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768820
[TBL] [Abstract][Full Text] [Related]
34. Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells.
Bruun J; Larsen TB; Jølck RI; Eliasen R; Holm R; Gjetting T; Andresen TL
Int J Nanomedicine; 2015; 10():5995-6008. PubMed ID: 26451106
[TBL] [Abstract][Full Text] [Related]
35. Tailored polymer-lipid hybrid nanoparticles for the delivery of drug conjugate: dual strategy for brain targeting.
Agrawal U; Chashoo G; Sharma PR; Kumar A; Saxena AK; Vyas SP
Colloids Surf B Biointerfaces; 2015 Feb; 126():414-25. PubMed ID: 25601092
[TBL] [Abstract][Full Text] [Related]
36. Novel delivery methods bypassing the blood-brain and blood-tumor barriers.
Hendricks BK; Cohen-Gadol AA; Miller JC
Neurosurg Focus; 2015 Mar; 38(3):E10. PubMed ID: 25727219
[TBL] [Abstract][Full Text] [Related]
37. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
[TBL] [Abstract][Full Text] [Related]
38. Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management.
Upadhaya PG; Pulakkat S; Patravale VB
Drug Deliv Transl Res; 2020 Aug; 10(4):1044-1056. PubMed ID: 32221847
[TBL] [Abstract][Full Text] [Related]
39. Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment.
Kang T; Zhu Q; Jiang D; Feng X; Feng J; Jiang T; Yao J; Jing Y; Song Q; Jiang X; Gao X; Chen J
Biomaterials; 2016 Sep; 101():60-75. PubMed ID: 27267628
[TBL] [Abstract][Full Text] [Related]
40. Design of new protein drug delivery system (PDDS) with photoactive compounds as a potential application in the treatment of glioblastoma brain cancer.
de Melo MT; Piva HL; Tedesco AC
Mater Sci Eng C Mater Biol Appl; 2020 May; 110():110638. PubMed ID: 32204072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
